Gene therapy, which promises a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward ...

(Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock ...

Reuters reported that President Trump’s tariffs have impacted the broader stock markets, weighing on investors’ sentiments, ...

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...

The gene therapy world is in turmoil, but Arbor, armed with more than a billion dollars in partnerships and raises, is going forward.

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

Sebastien Beauzile from Laurelton, Long Island, has become the first person in New York State to be cured of sickle cell ...